WMH and long-term outcomes in ischemic stroke: A systematic review and meta-analysis.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
19 03 2019
Historique:
received: 08 08 2018
accepted: 13 11 2018
pubmed: 17 2 2019
medline: 18 12 2019
entrez: 17 2 2019
Statut: ppublish

Résumé

To investigate the relationship between baseline white matter hyperintensities (WMH) in patients with ischemic stroke and long-term risk of dementia, functional impairment, recurrent stroke, and mortality. Following the Meta-analysis of Observational Studies in Epidemiology and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO protocol: CRD42018092857), we systematically searched Medline and Scopus for cohort studies of ischemic stroke patients examining whether MRI- or CT-assessed WMH at baseline are associated with dementia, functional impairment, recurrent stroke, and mortality at 3 months or later poststroke. We extracted data and evaluated study quality with the Newcastle-Ottawa scale. We pooled relative risks (RR) for the presence and severity of WMH using random-effects models. We included 104 studies with 71,298 ischemic stroke patients. Moderate/severe WMH at baseline were associated with increased risk of dementia (RR 2.17, 95% confidence interval [CI] 1.72-2.73), cognitive impairment (RR 2.29, 95% CI 1.48-3.54), functional impairment (RR 2.21, 95% CI 1.83-2.67), any recurrent stroke (RR 1.65, 95% CI 1.36-2.01), recurrent ischemic stroke (RR 1.90, 95% CI 1.26-2.88), all-cause mortality (RR 1.72, 95% CI 1.47-2.01), and cardiovascular mortality (RR 2.02, 95% CI 1.44-2.83). The associations followed dose-response patterns for WMH severity and were consistent for both MRI- and CT-defined WMH. The results remained stable in sensitivity analyses adjusting for age, stroke severity, and cardiovascular risk factors, in analyses of studies scoring high in quality, and in analyses adjusted for publication bias. Presence and severity of WMH are associated with substantially increased risk of dementia, functional impairment, stroke recurrence, and mortality after ischemic stroke. WMH may aid clinical prognostication and the planning of future clinical trials.

Identifiants

pubmed: 30770431
pii: WNL.0000000000007142
doi: 10.1212/WNL.0000000000007142
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1298-e1308

Subventions

Organisme : Medical Research Council
ID : MR/J006971/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 American Academy of Neurology.

Auteurs

Marios K Georgakis (MK)

From the Institute for Stroke and Dementia Research, University Hospital (M.K.G., M. Duering, M. Dichgans), and Graduate School for Systemic Neurosciences (M.K.G.), Ludwig-Maximilians-Universität LMU, Munich, Germany; Division of Neuroimaging Science (J.M.W.), Centre for Clinical Brain Science, Edinburgh Imaging and UK Dementia Research Institute, University of Edinburgh, UK; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Centre for Neurodegenerative Diseases (M. Dichgans), Munich, Germany.

Marco Duering (M)

From the Institute for Stroke and Dementia Research, University Hospital (M.K.G., M. Duering, M. Dichgans), and Graduate School for Systemic Neurosciences (M.K.G.), Ludwig-Maximilians-Universität LMU, Munich, Germany; Division of Neuroimaging Science (J.M.W.), Centre for Clinical Brain Science, Edinburgh Imaging and UK Dementia Research Institute, University of Edinburgh, UK; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Centre for Neurodegenerative Diseases (M. Dichgans), Munich, Germany.

Joanna M Wardlaw (JM)

From the Institute for Stroke and Dementia Research, University Hospital (M.K.G., M. Duering, M. Dichgans), and Graduate School for Systemic Neurosciences (M.K.G.), Ludwig-Maximilians-Universität LMU, Munich, Germany; Division of Neuroimaging Science (J.M.W.), Centre for Clinical Brain Science, Edinburgh Imaging and UK Dementia Research Institute, University of Edinburgh, UK; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Centre for Neurodegenerative Diseases (M. Dichgans), Munich, Germany.

Martin Dichgans (M)

From the Institute for Stroke and Dementia Research, University Hospital (M.K.G., M. Duering, M. Dichgans), and Graduate School for Systemic Neurosciences (M.K.G.), Ludwig-Maximilians-Universität LMU, Munich, Germany; Division of Neuroimaging Science (J.M.W.), Centre for Clinical Brain Science, Edinburgh Imaging and UK Dementia Research Institute, University of Edinburgh, UK; Munich Cluster for Systems Neurology (SyNergy) (M. Dichgans); and German Centre for Neurodegenerative Diseases (M. Dichgans), Munich, Germany. martin.dichgans@med.uni-muenchen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH